These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

240 related items for PubMed ID: 4456974

  • 41. Absence of relationships between L-dopa plasma levels and therapeutic effect in Parkinson's disease treated with L-dopa.
    Algeri S, Ruggieri S, Miranda F, Casacchia M, Morselli PL, Agnoli A.
    Eur Neurol; 1976; 14(3):219-28. PubMed ID: 1278194
    [Abstract] [Full Text] [Related]

  • 42. Effects of 3-OM-dopa on monoamine metabolism in rat brain.
    Gervas JJ, Muradás V, Bazán E, Aguado EG, de Yébenes JG.
    Neurology; 1983 Mar; 33(3):278-82. PubMed ID: 6681870
    [Abstract] [Full Text] [Related]

  • 43. Patterns of clinical response and plasma dopa levels in Parkinson's disease.
    Tolosa ES, Martin WE, Cohen HP, Jacobson RL.
    Neurology; 1975 Feb; 25(2):177-83. PubMed ID: 1167646
    [Abstract] [Full Text] [Related]

  • 44. L-dopa decarboxylation in chronically treated patients.
    Ward CD, Trombley IK, Calne DB, Kopin IJ.
    Neurology; 1984 Feb; 34(2):198-201. PubMed ID: 6538008
    [Abstract] [Full Text] [Related]

  • 45. Gastric emptying rate and the systemic availability of levodopa in the elderly parkinsonian patient.
    Evans MA, Broe GA, Triggs EJ, Cheung M, Creasey H, Paull PD.
    Neurology; 1981 Oct; 31(10):1288-94. PubMed ID: 7202139
    [Abstract] [Full Text] [Related]

  • 46. Defective 3,4-dihydroxyphenylalanine decarboxylation to dopamine in hydralazine-treated hypertensive patients may be pyridoxine remediable.
    Shigetomi S, Kuchel O.
    Am J Hypertens; 1993 Jan; 6(1):33-40. PubMed ID: 8427659
    [Abstract] [Full Text] [Related]

  • 47. Plasma DOPA and growth hormone in parkinsonism: oscillations in symptoms.
    Papavasiliou PS, McDowell FH, Wang YY, Rosal V, Miller ST.
    Neurology; 1979 Feb; 29(2):194-200. PubMed ID: 571063
    [Abstract] [Full Text] [Related]

  • 48. Dopaminergic abnormalities in hypertension associated with moderate renal insufficiency.
    Kuchel OG, Shigetomi S.
    Hypertension; 1994 Jan; 23(1 Suppl):I240-5. PubMed ID: 8282367
    [Abstract] [Full Text] [Related]

  • 49. Dopamine sulfate in ventricular cerebrospinal fluid and motor function in Parkinson's disease.
    Cedarbaum JM, Olanow CW.
    Neurology; 1991 Oct; 41(10):1567-70. PubMed ID: 1922797
    [Abstract] [Full Text] [Related]

  • 50. [Combined administration of cholinolytic metamizil and L-Dopa in vascular parkinsonism].
    Kamenetskiĭ VK.
    Klin Med (Mosk); 1978 Sep; 56(9):113-5. PubMed ID: 703225
    [No Abstract] [Full Text] [Related]

  • 51. Concentrations of tyrosine, L-dihydroxyphenylalanine, dopamine, and 3-O-methyldopa in the cerebrospinal fluid of Parkinson's disease.
    Tohgi H, Abe T, Takahashi S, Nozaki Y, Kikuchi T.
    Neurosci Lett; 1991 Jun 24; 127(2):212-4. PubMed ID: 1908962
    [Abstract] [Full Text] [Related]

  • 52. A semiautomated method for the rapid determination of dopa: comparison of plasma and erythrocyte-dopa concentration in levodopa-treated patients.
    Prasad AL, Fahn S.
    Biochem Med; 1982 Jun 24; 27(3):297-304. PubMed ID: 6810882
    [No Abstract] [Full Text] [Related]

  • 53. Levodopa, manganese, and degenerations of the brain.
    Cotzias GC.
    Harvey Lect; 1974 Jun 24; 68():115-47. PubMed ID: 4452625
    [No Abstract] [Full Text] [Related]

  • 54. [Effect of L-dopa on EEG tracings in patients with parkinsonism].
    Rudkowska A, Misztal S.
    Pol Tyg Lek; 1975 Apr 07; 30(14):593-5. PubMed ID: 1129202
    [No Abstract] [Full Text] [Related]

  • 55. Studies on the metabolism and excretion of L-3,4-dihydroxyphenylalanine (L-DOPA) in human beings by gas chromatography.
    Imai K, Sugiura M, Kubo H, Tamura Z, Oya K.
    Chem Pharm Bull (Tokyo); 1972 Apr 07; 20(4):759-64. PubMed ID: 5045616
    [No Abstract] [Full Text] [Related]

  • 56. Dopamine/L-dopa ratio in cerebrospinal fluid of parkinsonian patients treated with L-dopa + benserazide.
    Fekete M, Tárczy M, Bihari K, Katona G.
    Psychopharmacology (Berl); 1984 Apr 07; 82(1-2):93-4. PubMed ID: 6420835
    [Abstract] [Full Text] [Related]

  • 57.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 58. Phenylalanine absorption and metabolism in Parkinsonian patients.
    Granerus AK, Jagenburg R, Rödjer S, Svanborg A.
    Br Med J; 1971 Oct 30; 4(5782):262-4. PubMed ID: 5123908
    [Abstract] [Full Text] [Related]

  • 59. Induction of mania by L-dopa in a nonbipolar patient.
    Harsch HH, Miller M, Young LD.
    J Clin Psychopharmacol; 1985 Dec 30; 5(6):338-9. PubMed ID: 4066999
    [Abstract] [Full Text] [Related]

  • 60. Plasma catecholamines and the acute effects of oral L-dopa in Parkinsonian patients [proceedings].
    Brown MJ, Dollery CT, Reid JL, Rossor M, Watkins J.
    Br J Clin Pharmacol; 1979 Oct 30; 8(4):388P. PubMed ID: 508525
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.